专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明专利

AT279425T 未知
公开(公告)号：AT279425T
公开(公告)日：2004-10-15
申请号：AT01991315
申请日：2001-12-17
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , ZBAIDA SHMUEL , CHOWDHURY SWAPAN K , IANNUCCI ROBERT M , FENG WENQING , ALTON KEVIN B , PATRICK JAMES E , DAVIS HARRY R
IPC分类号： A61K31/00 , A61K31/366 , A61K31/397 , A61K31/70 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P3/06 , A61P9/10 , C07D205/08 , C07H15/26
摘要： please check closely-very confusing Hypocholesterolemic sugar-substituted 2-azetidinone compounds of the formula: are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

62. 发明专利

AU3104902A Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents 未知
公开(公告)号：AU3104902A
公开(公告)日：2002-07-01
申请号：AU3104902
申请日：2001-12-17
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , ZBAIDA SHMUEL , CHOWDHURY SWAPAN K , IANNUCCI ROBERT M , FENG WENQING , ALTON KEVIN B , PATRICK JAMES E , DAVIS HARRY R
IPC分类号： A61K31/00 , A61K31/366 , A61K31/397 , A61K31/70 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P3/06 , A61P9/10 , C07D205/08 , C07H15/26
摘要： please check closely-very confusing Hypocholesterolemic sugar-substituted 2-azetidinone compounds of the formula: are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

63. 发明专利

BRPI0617731A2 未知
公开(公告)号：BRPI0617731A2
公开(公告)日：2011-08-02
申请号：BRPI0617731
申请日：2006-10-18
申请人： SCHERING CORP
发明人： RAMANTHAN RAGULAN , GHOSAL ANIMA , MILLER MICHAEL W , CHOWDHURY SWAPAN K , ALTON KEVIN B
IPC分类号： C07D401/14 , A61K31/506 , A61P31/18 , A61P37/06 , C07H17/02
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

64. 发明专利

NO326981B1 未知
公开(公告)号：NO326981B1
公开(公告)日：2009-03-30
申请号：NO20032806
申请日：2003-06-19
申请人： SCHERING CORP
发明人： DAVIS HARRY R , PATRICK JAMES E , GHOSAL ANIMA , ZBAIDA SHMUEL , CHOWDHURY SWAPAN K , IANNUCCI ROBERT M , FENG WENQING , ALTON KEVIN B
IPC分类号： C07H15/26 , A61K31/00 , A61K31/366 , A61K31/397 , A61K31/70 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P3/06 , A61P9/10 , C07D205/08
摘要： please check closely-very confusing Hypocholesterolemic sugar-substituted 2-azetidinone compounds of the formula: are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

65. 发明专利

SK286703B6 Sugar-substituted 2-azetidinones, pharmaceutical preparation containing these compounds and use thereof 未知
公开(公告)号：SK286703B6
公开(公告)日：2009-03-05
申请号：SK7702003
申请日：2001-12-17
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , ZBAIDA SHMUEL , CHOWDHURY SWAPAN K , IANNUCCI ROBERT M , FENG WENQING , ALTON KEVIN B , PATRICK JAMES E , DAVIS HARRY R
IPC分类号： C07H15/00 , A61K31/00 , A61K31/366 , A61K31/397 , A61K31/70 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P3/06 , A61P9/10 , C07D205/08 , C07H15/26
摘要： Disclosed are sugar-substituted 2-azetidinone compounds of the formula (I) useful as hypocholesterolemic agents, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis and also for lowering cholesterol level.

66. 发明专利

NO20082297L 未知
公开(公告)号：NO20082297L
公开(公告)日：2008-07-21
申请号：NO20082297
申请日：2008-05-20
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , CHOWDHURY SWAPAN K , ALTON KEVIN B , MILLER MICHAEL W , RAMANATHAN RAGULAN
IPC分类号： C07D401/14 , A61K31/506 , A61P31/18 , A61P37/06 , C07H17/02
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

67. 发明专利

ES2287826T3 2-AZETIDINONAS SUSTITUIDAS CON HIDROXI UTILES COMO AGENTES HIPOCOLESTEROLEMICOS. 未知
公开(公告)号：ES2287826T3
公开(公告)日：2007-12-16
申请号：ES05004699
申请日：2001-12-17
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , ZBAIDA SHMUEL , CHOWDHURY SWAPAN K , IANNUCCI ROBERT M , FENG WENQING , ALTON KEVIN B
IPC分类号： C07D205/08 , A61K31/00 , A61K31/366 , A61K31/397 , A61K31/70 , A61K31/7052 , A61K45/00 , A61K45/06 , A61P3/06 , A61P9/10 , C07H15/26
摘要： Un compuesto representado por la fórmula estructural I: o una de sus sales farmacéuticamente aceptable, en donde R26 se selecciona del grupo formado por: a) flúor y b) cloro, R1 es H, Ar1 es arilo o arilo sustituido con R10; Ar2 es arilo o arilo sustituido con R11: Q es -(CH2)q-, en donde q es 2-6 o, con el carbono en la posición 3 del anillo de la azetidinona, forma el grupo espiro ; R12 es | | | | | | | -CH-, -C(alquilo C1-C6)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N- o -+NO- ; | R13 y R14 se seleccionan, independientemente, del grupo formado por -CH2-, -CH(alquilo C1-C6)-, -C(dialquilo (C1-C6)), -CH=CH- y -C(alquil C1-C6)=CH-; o R12, junto con un R13 adyacente, o R12 junto con un R14 adyacente, forman un grupo -CH=CH- o -CH=C(alquilo C1-C6)-; a y b son, independientemente, 0, 1, 2 ó 3, con la condición de que ambos no sean cero; con la condición de que R13 sea -CH=CH- o -C(alquil C1-C6)=CH-, a es 1; con la condición de que R14 sea -CH=CH- o -C(alquilo C1-C6)=CH-, b es 1; con la condición deque a es 2 ó 3, los R13 pueden ser iguales o diferentes; y con la condición de que b sea 2 ó 3, los R14 pueden ser iguales o diferentes; R10 y R11 se seleccionan, independientemente, del grupo formado por 1-3 sustituyentes seleccionados independientemente del grupo formado por alquilo (C1-C6), -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)OR20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, S(O)0-2R21, -O(CH2)1-10COOR19, -O(CH2)1-10CONR19R20, -(alquileno C1-C5)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 y halógeno; Ar1 también puede ser piridilo, isoxazolilo, furanilo, pirrolilo, tienilo, imidazolilo, pirazolilo, tiazolilo, pirazinilo, pirimidinilo o piridazinilo; R19 y R20 se seleccionan independientemente del grupo formado por H, alquilo (C1-C6), arilo y alquilo (C1-C6) sustituido con arilo; R21 es alquilo (C1-C6), arilo o arilo sustituido con R24; R22 es H, alquilo (C1-C6), aril-alquilo (C1-C6), -C(O)R19 o -COOR19; R23 y R24 son independientemente 1-3 grupos seleccionados independientemente del grupo formado por H, alquilo (C1-C6), alcoxi (C1-C6), -COOH, NO2, -NR19R20, -OH y halógeno; y R25 es H, -OH o alcoxi (C1-C6).

68. 发明专利

CA2647158A1 COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO 未知
公开(公告)号：CA2647158A1
公开(公告)日：2007-10-04
申请号：CA2647158
申请日：2007-03-19
申请人： SCHERING CORP
发明人： RALSTON ROBERT O II , GHOSAL ANIMA , TREITEL MICHELLE A , WHITE RONALD E , MCLEOD JAMES F , STRIZKI JULIE M , GUPTA SAMIR K , O'MARA EDWARD M , VLACH JAROMIR
IPC分类号： A61K31/16 , A61K31/192 , A61K31/196 , A61K31/343 , A61K31/395 , A61K31/40 , A61K31/403 , A61K31/427 , A61K31/454 , A61K31/496 , A61K31/4965 , A61K38/06 , A61K38/07 , A61K45/06 , A61P31/12
摘要： Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV.

69. 发明专利

DE602004006756D1 未知
公开(公告)号：DE602004006756D1
公开(公告)日：2007-07-12
申请号：DE602004006756
申请日：2004-07-29
申请人： SCHERING CORP
发明人： GHOSAL ANIMA , TONG WEI , CHOWDHURY SWAPAN K , ZBAIDA SHMUEL , WIRTH MARK A , ALTON KEVIN B , PATRICK JAMES E , BOYLE CRAIG D , STAMFORD ANDREW
IPC分类号： C07D473/06 , A61K31/522
摘要： The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. Further disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.

70. 发明专利

CO5650249A2 METABOLITOS DE AMIDAS TRICICLICAS UTILES PARA LA INHIBICION DE LA FUNCION DE LA PROTEINA G Y METODOS DE TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS 未知
公开(公告)号：CO5650249A2
公开(公告)日：2006-06-30
申请号：CO05128765
申请日：2005-12-22
申请人： SCHERING CORP
发明人： CHOWDHURY SWAPAN , GHOSAL ANIMA , IANNUCCI ROBERT M , FENG WENGING , CHANG TZE-MING , ZBAIDA SHMUEL , ALTON KEVIN B , DOLL RONALD J , MINOR KEITH P
IPC分类号： A61K31/435 , A61K31/4545 , A61P35/00 , C07D401/14
摘要： 1.- Un compuesto representado por la fórmula estructural (I): y los isómeros, sales, solvatos o ésteres farmacéuticamente aceptables del compuesto de fórmula (I):en la cual:R1 está seleccionado del grupo que consiste en H y =O;R2-R5 pueden ser iguales o diferentes, y cada uno está independientemente seleccionado del grupo que consiste en H, -OH, haluro, -NH2 y =O;y, la combinación de líneas llenas y líneas de trazos representa independientemente, enlaces simples o bien enlaces dobles, donde la cantidad de combinaciones de líneas llenas y líneas de trazos que son enlaces dobles no es superior a 2, y cuando es 2, los enlaces dobles no son adyacentes, y cuando es 0, uno de R1-R5 no es H.2.- El compuesto de la reivindicación 1 en el cual: R1, R2, R3, y R5, son cada uno H, R4 está seleccionado del grupo que consiste en H y -OH, y la cantidad de combinaciones de líneas llenas y líneas de trazos que son enlaces dobles no es superior a 1.3.- El compuesto de la reivindicación 1, representado por la fórmula y los isómeros, sales, solvatos o ésteres del mismo farmacéuticamente aceptables.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式